



March 11, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Intimation of Acquisition of 1,33,332 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company by way of subscription to the right issue

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we Zota Health Care Limited (the “Company”) would like to inform you that the Company has acquired 1,33,332 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary (“WOS”) of the Company by way of subscription to the right issue.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is annexed herewith as **Annexure-I**.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

Annexure-I

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc	<p>i. Name of the Target Entity: Davaindia Health Mart Limited (“DIHML”)</p> <p>ii. Business of the Target Entity: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy.</p> <p>iii. Financial details: as per the audited financial statements for the Financial Year 2023-24, the turnover of DIHML was Rs. 44.77 crores and the total paid up share capital was Rs. 2.00 crores.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition does not fall within related party transactions. The promoter/ promoter group/ group companies do not have any interest in DIHML.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has made further investment in DIHML as a part of strategic investment and working capital requirements of WOS. Post to this acquisition DIHML continues to remain as the WOS of the Company.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On March 11, 2025 the Company has acquired the said 1,33,332 equity shares of DIHML.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of Equity Shares
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for the right issue of 1,33,332 Equity Shares is Rs. 4155/- per equity share (including premium of Rs. 4145/- per equity share) aggregating to Rs. 55,39,94,460/-.
Percentage of shareholding / control acquired and / or number of shares acquired	The company has further acquired 1,33,332 equity shares of DIHML. Post to this acquisition the DIHML continues to remain as the WOS of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>DIHML was incorporated on January 01, 2020, domiciled in India; operating Company Owned Company Operated (COCO) stores of Davaindia Generic Pharmacy having store presence in 15+ states with ~780+ stores and offering 2000+ SKUs inclusive of Medicines, Ayurvedic, Cosmetics, Nutraceutical and OTC products.</p> <p>During last three financial years the details of turnover of DIHML were as follows: FY 2023-24 Rs. 44.77 crores FY 2022-23 Rs. 14.61 crores FY 2021-22 Rs. 1.60 crores</p>